◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocksELV › Revenue

Elevance Health Inc (ELV) Revenue 2006–TTM

DATA UPDATED 2026-07-13

Elevance Health Inc annual revenue for fiscal TTM was $200.4 billion, an increase of 0.6% from $199.1 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ELV Annual Revenue

Revenue (annual)TTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$200.4B$199.1B$176.8B$171.3B$156.6B$138.6B$121.9B$104.2B$92.1B$90.0B$85.0B$79.2B$73.9B$71.1B$61.5B$60.8B$58.8B$61.6B$62.5B$61.4B$57.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ELV Quarterly Revenue

Revenue (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$50.2B$49.7B$50.7B$49.8B$48.9B$45.4B$45.1B$43.6B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More ELV metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All ELV financial statements → Interactive ELV charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.